| 영문 | vaccine | 한글 | 백신 |
|---|---|---|---|
| 설명 | 전염병에 대하여 인공적으로 면역을 주기 위해 생체에 투여하는 항원의 하나. 병원체 및 독소에 대한 방어기구를 강화할 목적으로 사용되는 미생물제제를 말한다. 프랑스의 미생물학자 L. 파스퇴르에 의하여 제창된 용어로서, 어떤 감염증에 대하여 인공적으로 면역을 얻기 위하여 그 병원 미생물 또는 그 독소액에 적당한 조작을 가하여 만든 것을 말한다. |
||
| MM | macromolecule; Maelzels metronome; major medical [insurance]; malignant melanoma; manubrium to malle... |
|---|---|
| SMCD | senile macular choroidal degeneration; systemic mast cell disease; systemic meningococcal disease |
| DEV | Duck Embryo Vaccine |
| HBPV | Haemophilus influenza type B Polysaccharide(PRP) Vaccine; B형 헤모필루스 인플루엔자 피막 다당질 백신... |
| HDCV | Human Diploid Cell Vaccine; 인간 이배체 세포 백신 |
| MD | Meningococcal Disease |
|---|---|
| MCD | Meningococcal disease |
| BPV | Bordatella pertussis vaccine |
| DTP | Diphtheria-tetanus-pertussis vaccine |
| Hib | Haemophilus influenzae type b vaccine |
| acute fulminating meningococcal septicaemia | <radiology> Septicaemia (e.g., meningococcaemia), haemorrhagic necrosis of adrenals due to, septic emboli, disseminated intravascular coagulopathy (DIC), most likely to be adrenal haemorrhage and/or calcification (12 Dec 1998) |
|---|---|
| meningitis, meningococcal | Inflammation in response to infection with neisseria meningitidis of the pia-arachnoid and the fluid residing in the space which it encloses as well as the fluid in the ventricles of the brain. This condition occurs most often in children and adolescents. (12 Dec 1998) |
| meningococcal infections | Infections with bacteria of the species neisseria meningitidis. (12 Dec 1998) |
| meningococcal meningitis | An acute infectious disease affecting children and young adults, caused by Neisseria meningitidis; characterised by nasopharyngeal catarrh, headache, vomiting, convulsions, stiffness in the neck (nuchal rigidity), photophobia, constipation, cutaneous hyperesthesia, a purpuric or herpetic eruption, and the presence of Kernig's sign. Fulminant form may cause Waterhouse-Friderichsen syndrome. Synonym: cerebrospinal fever, epidemic cerebrospinal meningitis. (05 Mar 2000) |
| acellular vaccine | <immunology, pharmacology, virology> Vaccine consisting of antigenic parts of cells. (13 Nov 1997) |
| adjuvant vaccine | A vaccine that contains an adjuvant; most often the antigen (immunogen) is included in a water-in-oil emulsion (Freund incomplete type adjuvant), or is adsorbed onto an inorganic gel (alum, aluminum hydroxide or phosphate). (05 Mar 2000) |
| aqueous vaccine | A vaccine having a liquid vehicle (e.g., physiological salt solution) as distinguished from an emulsion. (05 Mar 2000) |
| attenuated vaccine | Live pathogens that have lost their virulence but are still capable of inducing a protective immune response to the virulent forms of the pathogen, e.g., Sabin polio vaccine. (05 Mar 2000) |
| autogenous vaccine | A vaccine made from a culture of the patient's own bacteria. (05 Mar 2000) |
| bacillus Calmette-Guerin vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
| BCG vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
| brucella strain 19 vaccine | A live bacterial vaccine prepared from an attenuated variant strain of Brucella abortus (strain 19); used for vaccinating cattle against brucellosis. (05 Mar 2000) |
| brucella vaccine | A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats. (12 Dec 1998) |
| Calmette-Guerin vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
| rabies vaccine | An inactivated virus vaccine, used for preexposure immunization to persons at high risk of exposure, e.g., veterinarians, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. The official preparation is human diploid cell vaccine produced from rabies virus grown in cultures of human diploid embryo lung cells and inactivated with propriolactone. It has a much lower incidence of adverse reactions than the previously used duck embryo vaccine. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|